MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/sla.0000000000005742

Медицинская библиотека · Annals of surgery · 2022

An International Multicenter Prospective Study Evaluating the Long-term Oncological Impact of Adjuvant Chemotherapy in ypN+ Rectal Cancer.

Denost Quentin, Fleming Christina A, Burghgraef Thijs, Celerier Bertrand, Geitenbeek Ritchie, Rullier Eric, Tuynman Jurriaan, Consten Esther, Hompes Roel, Dutch MIRECA Collaborative Group (Pubmed Citable)

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To assess the oncological benefit of adjuvant chemotherapy (AC) in node positive (ypN+) rectal cancer after neoadjuvant chemoradiotherapy and radical surgery.

BACKGROUND

The evidence for AC after total mesorectal excision for locally advanced rectal cancer is conflicting and the net survival benefit is debated.

METHODS

An international multicenter comparative cohort study was performed comparing oncological outcomes in tertiary rectal cancer centers from the Netherlands and France. Patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery and with positive lymph nodes on histologic examination (ypN+) were included for analysis. Kaplan-Meier curves were generated to compare disease-free (DFS) and overall survival in AC and non-AC groups.

RESULTS

Of 1265 patients screened, a total of 239 rectal cancer patients with ypN+ disease were included. Demographic and clinical characteristics were similar in both groups. Higher systemic recurrence rates were observed in the non-AC group compared with those who received AC [32.0% (n=40) vs 17.5% (n=11), respectively, P =0.034]. DFS at 1 and 5 years postoperatively were significantly better in the AC group (92% vs 80% at 1 year; 72% vs 51% at 5 years, P =0.024), whereas no difference in overall survival was observed.

CONCLUSIONS

In this multicenter comparative cohort study, we identified an oncological benefit of AC in both systemic recurrence and DFS in ypN+ rectal cancer patients. From this data, systemic chemotherapy continues to confer oncological benefit in locally advanced ypN+ rectal cancer.

Для цитирования: Denost Quentin, Fleming Christina A, Burghgraef Thijs, Celerier Bertrand, Geitenbeek Ritchie, Rullier Eric, Tuynman Jurriaan, Consten Esther, Hompes Roel, Dutch MIRECA Collaborative Group (Pubmed Citable). An International Multicenter Prospective Study Evaluating the Long-term Oncological Impact of Adjuvant Chemotherapy in ypN+ Rectal Cancer.. Annals of surgery. 2022. DOI: 10.1097/sla.0000000000005742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.